Kalaris Therapeutics, Inc. (KLRS)

9.13 -1.29 (-12.38%) USD  |  NASDAQ  |  Dec 19, 16:00
9.41 +0.28 (+3.07%) Pre-Market: 08:10
More

Kalaris Therapeutics Total Expenses (Quarterly)

Total Expenses (Quarterly) Chart

View Total Expenses (Quarterly) for KLRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Expenses (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Total Expenses (Quarterly) Range, Past 5 Years

View Total Expenses (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Expenses (Quarterly) Benchmarks

View Total Expenses (Quarterly) Benchmarks
Start Trial
CEL-SCI Corp. Upgrade
AIM ImmunoTech, Inc. Upgrade
IGC Pharma, Inc. Upgrade
NovaBay Pharmaceuticals, Inc. Upgrade
Protalix Biotherapeutics, Inc. Upgrade

Total Expenses (Quarterly) Related Metrics

Net Income (Quarterly) Upgrade
EPS Diluted (Quarterly) Upgrade
Enterprise Value Upgrade
Earnings Yield Upgrade
Normalized Earnings Yield Upgrade